Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to $23.6 million.

  • Mirum Pharmaceuticals' Depreciation & Amortization (CF) rose 0.12% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 5.02%. This contributed to the annual value of $23.6 million for FY2024, which is 118.20% up from last year.
  • Mirum Pharmaceuticals' Depreciation & Amortization (CF) amounted to $23.6 million in FY2024, which was up 118.20% from $10.8 million recorded in FY2023.
  • Mirum Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $23.6 million for FY2024, and its period low was $305,000 during FY2020.
  • In the last 3 years, Mirum Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $10.8 million in 2023 and averaged $12.6 million.
  • Data for Mirum Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY soared of 444.20% (in 2022) over the last 5 years.
  • Mirum Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $305,000 in 2020, then surged by 95.08% to $595,000 in 2021, then spiked by 444.20% to $3.2 million in 2022, then skyrocketed by 234.43% to $10.8 million in 2023, then surged by 118.20% to $23.6 million in 2024.